GlassScriptPhysician profile
Arcadio L Dumpit
NPI 1699078766
$422.30
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $218 · 2020: $84.39 · 2021: $76.98 · 2022: $43.21.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $79.28 | 2019 | |
| Pfizer INC. | $71.86 | 2019-2021 | |
| Sunovion Pharmaceuticals INC. | $55.57 | 2019 | |
| Amgen INC. | $41.98 | 2020 | |
| Janssen Pharmaceuticals, INC | $40.88 | 2021-2022 | |
| Lilly USA, LLC | $26.96 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $25.83 | 2019-2021 | |
| Smith+Nephew, INC. | $22.51 | 2019 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $22.35 | 2022 | |
| Supernus Pharmaceuticals, INC. | $19.94 | 2021 | |
| Sk Life Science, INC. | $15.14 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arcadio Dumpit listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.